348 related articles for article (PubMed ID: 28257806)
21. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
Xu J; Wang B; Xu Y; Sun L; Tian W; Shukla D; Barod R; Grillari J; Grillari-Voglauer R; Maxwell PH; Esteban MA
Oncogene; 2012 Feb; 31(8):1065-72. PubMed ID: 21841824
[TBL] [Abstract][Full Text] [Related]
23. Dual Strands of Pre-miR-149 Inhibit Cancer Cell Migration and Invasion through Targeting FOXM1 in Renal Cell Carcinoma.
Okato A; Arai T; Yamada Y; Sugawara S; Koshizuka K; Fujimura L; Kurozumi A; Kato M; Kojima S; Naya Y; Ichikawa T; Seki N
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902136
[TBL] [Abstract][Full Text] [Related]
24. A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma.
Salama MF; Carroll B; Adada M; Pulkoski-Gross M; Hannun YA; Obeid LM
FASEB J; 2015 Jul; 29(7):2803-13. PubMed ID: 25805832
[TBL] [Abstract][Full Text] [Related]
25. Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways.
Lichner Z; Mejia-Guerrero S; Ignacak M; Krizova A; Bao TT; Girgis AH; Youssef YM; Yousef GM
Am J Pathol; 2012 Apr; 180(4):1675-87. PubMed ID: 22326755
[TBL] [Abstract][Full Text] [Related]
26. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC
Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146
[TBL] [Abstract][Full Text] [Related]
27. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.
Clark PE
Kidney Int; 2009 Nov; 76(9):939-45. PubMed ID: 19657325
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer.
Hirata H; Hinoda Y; Ueno K; Nakajima K; Ishii N; Dahiya R
Carcinogenesis; 2012 Mar; 33(3):501-8. PubMed ID: 22180573
[TBL] [Abstract][Full Text] [Related]
29. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis.
White NM; Masui O; Newsted D; Scorilas A; Romaschin AD; Bjarnason GA; Siu KW; Yousef GM
Br J Cancer; 2014 Mar; 110(5):1250-9. PubMed ID: 24496460
[TBL] [Abstract][Full Text] [Related]
30. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
31. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-30a-5p Inhibits the Growth of Renal Cell Carcinoma by Modulating GRP78 Expression.
Wang C; Cai L; Liu J; Wang G; Li H; Wang X; Xu W; Ren M; Feng L; Liu P; Zhang C
Cell Physiol Biochem; 2017; 43(6):2405-2419. PubMed ID: 29073630
[TBL] [Abstract][Full Text] [Related]
33. Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate.
Merlo A; Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Pitiot AS; Balbín M; Astudillo A; Valdés N; Scola B; Del Toro R; Méndez-Ferrer S; Piruat JI; Suarez C; Chiara MD
Oncotarget; 2017 Jan; 8(4):6700-6717. PubMed ID: 28036268
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor modulates metastatic routes of VHL wild-type clear cell renal cell carcinoma in an oxygen-dependent manner.
Huang Q; Sun Y; Zhai W; Ma X; Shen D; Du S; You B; Niu Y; Huang CP; Zhang X; Chang C
Oncogene; 2020 Oct; 39(43):6677-6691. PubMed ID: 32943729
[TBL] [Abstract][Full Text] [Related]
35. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST
PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124
[TBL] [Abstract][Full Text] [Related]
36. (1)H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism.
Cuperlovic-Culf M; Cormier K; Touaibia M; Reyjal J; Robichaud S; Belbraouet M; Turcotte S
Int J Cancer; 2016 May; 138(10):2439-49. PubMed ID: 26620126
[TBL] [Abstract][Full Text] [Related]
37. miRNA-221 promotes proliferation, migration and invasion by targeting TIMP2 in renal cell carcinoma.
Lu GJ; Dong YQ; Zhang QM; Di WY; Jiao LY; Gao QZ; Zhang CG
Int J Clin Exp Pathol; 2015; 8(5):5224-9. PubMed ID: 26191221
[TBL] [Abstract][Full Text] [Related]
38. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
Shang D; Liu Y; Yang P; Chen Y; Tian Y
Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
40. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.
Ruf M; Mittmann C; Nowicka AM; Hartmann A; Hermanns T; Poyet C; van den Broek M; Sulser T; Moch H; Schraml P
Clin Cancer Res; 2015 Feb; 21(4):889-98. PubMed ID: 25691774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]